Sinovac Biotech [SVA] vs W.K. Kellogg [KLG] Detailed Stock Comparison
Sinovac Biotech
NASDAQ
Loading...
W.K. Kellogg
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Sinovac Biotech wins in 8 metrics, W.K. Kellogg wins in 10 metrics, with 0 ties. W.K. Kellogg appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Sinovac Biotech | W.K. Kellogg | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 6.66 | 67.65 | Sinovac Biotech |
| Price-to-Book Ratio | 0.05 | 5.75 | Sinovac Biotech |
| Debt-to-Equity Ratio | 0.02 | 249.57 | Sinovac Biotech |
| PEG Ratio | 0.02 | -0.89 | W.K. Kellogg |
| EV/EBITDA | -4.52 | 10.25 | Sinovac Biotech |
| Profit Margin (TTM) | 59.51% | 1.15% | Sinovac Biotech |
| Operating Margin (TTM) | -33.63% | 5.87% | W.K. Kellogg |
| EBITDA Margin (TTM) | N/A | 5.87% | N/A |
| Return on Equity | -0.88% | 8.81% | W.K. Kellogg |
| Return on Assets (TTM) | -0.78% | 5.69% | W.K. Kellogg |
| Free Cash Flow (TTM) | $-41.69M | $-22.00M | W.K. Kellogg |
| Dividend Yield | 1,700.15% | 3.13% | Sinovac Biotech |
| 1-Year Return | 0.00% | 29.50% | W.K. Kellogg |
| Price-to-Sales Ratio (TTM) | 1.43 | 0.76 | W.K. Kellogg |
| Enterprise Value | $-328.71M | $2.73B | W.K. Kellogg |
| EV/Revenue Ratio | -0.73 | 1.05 | Sinovac Biotech |
| Gross Profit Margin (TTM) | 86.71% | 27.24% | Sinovac Biotech |
| Revenue per Share (TTM) | $5 | $30 | W.K. Kellogg |
| Earnings per Share (Diluted) | $-1.06 | $0.34 | W.K. Kellogg |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Sinovac Biotech vs W.K. Kellogg Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Sinovac Biotech | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| W.K. Kellogg | 0.13% | -0.30% | -1.46% | 28.48% | 15.73% | 28.99% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Sinovac Biotech | 0.00% | 0.00% | 0.00% | 15.95% | 71.16% | 75.34% |
| W.K. Kellogg | 29.50% | 120.98% | 120.98% | 120.98% | 120.98% | 120.98% |
Performance & Financial Health Analysis: Sinovac Biotech vs W.K. Kellogg
| Metric | SVA | KLG |
|---|---|---|
| Market Information | ||
| Market Cap | $642.44M | $1.99B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | N/A | 847,580 |
| 90 Day Avg. Volume | N/A | 2,778,590 |
| Last Close | $6.47 | $22.99 |
| 52 Week Range | $6.47 - $6.47 | $14.80 - $23.56 |
| % from 52W High | 0.00% | -2.42% |
| All-Time High | $12.50 (Aug 31, 2009) | $24.63 (Apr 22, 2024) |
| % from All-Time High | -48.24% | -6.66% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 1.84% | -0.09% |
| Quarterly Earnings Growth | 3.04% | -0.78% |
| Financial Health | ||
| Profit Margin (TTM) | 0.60% | 0.01% |
| Operating Margin (TTM) | -0.34% | 0.06% |
| Return on Equity (TTM) | -0.01% | 0.09% |
| Debt to Equity (MRQ) | 0.02 | 249.57 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $121.57 | $4.00 |
| Cash per Share (MRQ) | N/A | $1.40 |
| Operating Cash Flow (TTM) | $113.55M | $79.00M |
| Levered Free Cash Flow (TTM) | $-105,900,000 | $-113,000,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 1,700.15% | 3.13% |
| Last 12-Month Dividend | $110.00 | $0.49 |
Valuation & Enterprise Metrics Analysis: Sinovac Biotech vs W.K. Kellogg
| Metric | SVA | KLG |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 6.66 | 67.65 |
| Forward P/E | -53.92 | 16.55 |
| PEG Ratio | 0.02 | -0.89 |
| Price to Sales (TTM) | 1.43 | 0.76 |
| Price to Book (MRQ) | 0.05 | 5.75 |
| Market Capitalization | ||
| Market Capitalization | $642.44M | $1.99B |
| Enterprise Value | $-328,711,264 | $2.73B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | -0.73 | 1.05 |
| Enterprise to EBITDA | -4.52 | 10.25 |
| Risk & Other Metrics | ||
| Beta | N/A | N/A |
| Book Value per Share (MRQ) | $121.57 | $4.00 |
Financial Statements Comparison: Sinovac Biotech vs W.K. Kellogg
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | SVA | KLG |
|---|---|---|
| Revenue/Sales | $327.45M | $613.00M |
| Cost of Goods Sold | $43.53M | $446.00M |
| Gross Profit | $283.93M | $167.00M |
| Research & Development | $2.66M | N/A |
| Operating Income (EBIT) | $197.04M | $24.00M |
| EBITDA | $200.07M | $53.00M |
| Pre-Tax Income | $198.37M | $11.00M |
| Income Tax | $25.67M | $3.00M |
| Net Income (Profit) | $172.70M | $8.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | SVA | KLG |
|---|---|---|
| Cash & Equivalents | $1.27B | $120.00M |
| Total Current Assets | $11.83B | $742.00M |
| Total Current Liabilities | $1.15B | $749.00M |
| Long-Term Debt | $217.09M | $775.00M |
| Total Shareholders Equity | $12.02B | $345.00M |
| Retained Earnings | $7.12B | $26.00M |
| Property, Plant & Equipment | $45.53M | $2.97B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | SVA | KLG |
|---|---|---|
| Operating Cash Flow | $455.16M | $64.00M |
| Capital Expenditures | $-57.70M | $-64.00M |
| Free Cash Flow | $423.23M | $-39.00M |
| Debt Repayment | $-6.58M | $-101.00M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | SVA | KLG |
|---|---|---|
| Shares Short | N/A | 6.66M |
| Short Ratio | N/A | 1.89 |
| Short % of Float | N/A | 0.14% |
| Average Daily Volume (10 Day) | N/A | 847,580 |
| Average Daily Volume (90 Day) | N/A | 2,778,590 |
| Shares Outstanding | 99.64M | 86.10M |
| Float Shares | N/A | 75.00M |
| % Held by Insiders | N/A | 0.13% |
| % Held by Institutions | N/A | 0.99% |
Dividend Analysis & Yield Comparison: Sinovac Biotech vs W.K. Kellogg
| Metric | SVA | KLG |
|---|---|---|
| Last 12-Month Dividend | $110.00 | $0.49 |
| Last 12-Month Dividend Yield | 1,700.15% | 3.13% |
| 3-Year Avg Annual Dividend | $36.67 | $0.32 |
| 3-Year Avg Dividend Yield | 850.08% | 0.99% |
| 3-Year Total Dividends | $110.00 | $0.97 |
| Ex-Dividend Date | Jul 10, 2025 | Feb 28, 2025 |